It’s a big day for Revive Therapeutics (CSE: RVV) (OTC: RVVTF). The company announced this morning that the US Food and Drug Administration has approved the company’s application for a Phase 3 Clinical Trial for the study of utilizing Bucillamine in the treatment of patients with mild-moderate COVID-19. The Phase 3 clinical trial will see … Continue reading Revive Therapeutics Granted FDA Approval For Phase 3 Clinical Trial For Bucillamine In COVID-19 Treatment